Everything else that changed in those six weeks
The problem is not that the people posting are lying. Most are not. The problem is that the format cannot answer the question it appears to answer, and the reasons are ordinary rather than technical.
Every row is a live explanation for the change, and the format cannot exclude a single one. That is the whole argument. A before and after is not weak evidence because photos can be faked. It is weak because even a completely honest one is compatible with the peptide having done nothing at all.
| What else was going on | Why it moves the outcome | Can the two photos rule it out? |
|---|---|---|
| Time | Most soft tissue injuries improve on their own, on a timescale close to the length of a typical peptide cycle | No |
| Reduced load | People who start a recovery protocol usually also stop doing the thing that hurt | No |
| Physiotherapy or rehab work | Often started in the same week, and has actual trial evidence behind it in humans | No |
| Other products started at once | Peptides are rarely bought alone, and the effect gets credited to the newest item | No |
| Expectation | Pain report shifts with belief, which is why medicine uses blinded comparisons in humans | No |
| Photo conditions | Lighting, angle, posture, hydration and time of day change an image without changing tissue | No |
| Who chose to post | People who improved post, people who did not usually go quiet | No |
What the format structurally cannot separate
Three separations do the heavy lifting in real evidence, and none of them survives this format.
It cannot separate the treatment from the passage of time. Without someone comparable who did not take it, healing and recovery look identical from the inside. This is precisely why a control group exists, and it is the first thing a testimonial lacks.
It cannot separate the treatment from everything else that started that week. Almost nobody adds one variable in isolation. Rest, rehabilitation, better sleep, a deload, an anti inflammatory and a new peptide often begin within days of each other, and the newest and most expensive item collects the credit.
It cannot separate the experience from the measurement. Pain and stiffness are reported by the person who paid, which is not a criticism of anyone's honesty. It is the reason blinded comparison exists in humans at all. When the person assessing the result also chose to buy it, expectation is baked into the reading.
Related reading on this compound: [what BPC-157 actually is](/blog/what-is-bpc-157), [the dosing question](/blog/bpc-157-dosage), [the benefit claims graded by organism](/blog/bpc-157-benefits).
What the regulated market does instead
There is a reason licensed medicines are not marketed with transformation photographs, and it is not modesty. Regulators do not accept the format, so companies had to build something more expensive.
That something is the controlled trial: a comparison group, allocation the participant does not choose, an outcome measure fixed before anyone enrols, and analysis of everybody who started rather than everybody who finished. Each element exists to close one of the gaps listed above. Together they cost a great deal, which is exactly why an unapproved product's marketing falls back on the one format that costs nothing.
When you compare a peptide seller's evidence against a pharmacy medicine's, you are not comparing two sets of proof of different strength. You are comparing evidence against anecdote, and the anecdote is more emotionally compelling by design.
The history behind that rule is worth a sentence, because it explains why the restriction feels so heavy handed. Advertising rules on health claims exist because testimonials were the standard sales tool for a long stretch of the last century, across products that turned out to do nothing and products that turned out to do harm. The format was not banned for being unreliable in theory. It was restricted after decades of it working extremely well on people who had no way to check.
BPC-157 before and after inside a clinic file
Some providers keep their own records, and a consumer is entitled to ask about them. It is worth knowing what such a file can and cannot support.
A clinic's records are a case series: a set of people who came, paid, and were noted down. They are useful for spotting an unexpected safety signal, and for a provider's own learning. What they cannot do is establish effect, because everyone in the file chose the treatment, nobody was compared against anyone, and the people who did not return are absent from the totals.
There is also a selection effect that is easy to miss. The person showing you results chose which ones to show. That is not necessarily dishonest, since anyone summarising picks examples. It does mean the file cannot function as evidence in the way its presentation implies.
A fair question to put to a provider is what proportion of their patients they lost track of, and what happened to the ones who stopped early. A provider who has thought about this will have an answer, even an uncomfortable one, and that answer tells you more about how carefully they think than any photograph on the wall.
Meanwhile, the underlying research remains what it is: an efficacy literature that is overwhelmingly rat and cell culture work, much of it from a small number of research groups, covering tendon, ligament, muscle and gut outcomes. No published human efficacy result exists to set beside anyone's photographs.
The pictures that would actually settle it
Human trials are registered, and this is the half that people arguing against the peptide tend to leave out. NCT07803250 is a Phase 1 trial of 30 participants covering rotator cuff repair recovery and is not yet recruiting. NCT02637284 is a Phase 1 safety and pharmacokinetics study of 42 participants with a status listed as unknown.
None has published efficacy results. If they report, what they will produce is the thing a testimonial cannot: outcomes in people who did not know what they received, measured the way the plan said they would be measured, including the ones who got worse. That is what a before and after would look like if it were built to be checked rather than to be shared.
A short checklist for the next post you read
The next BPC-157 before and after you read will tell you more if you put five questions to it.
Ask what else started that week. If the answer is nothing at all, ask again, because it is almost never nothing.
Ask how long the injury had been present and what its normal course looks like. An injury three weeks old was going to improve anyway, and a peptide started at week three will be credited for week six.
Ask who is not in the picture. Any single success implies an unknown number of people who tried the same thing and had nothing to post.
Ask whether the person is selling something, including attention. A commercial interest does not make a report false, but it decides which reports you are shown.
Finally, ask what result would have changed their mind. Anyone who cannot name one is describing a belief rather than a finding, and that is fine as long as you are pricing it accordingly.